Rezultati pretraživanja
  1. 3. velj

    United Therapeutics Lifted to “Overweight” at JPMorgan Chase & Co.

  2. 3. velj

    Biotech updates 02/03: Ph2 +ve data +41% Fast track desig+15% offering -12% AH Phase 2/3 SCLC fail -2% 1:20 reverse split (02/11) Pipeline updates:

  3. 3. velj

    United Therapeutics' drug fails PhII/III cancer trial, marking their second straight stumble in push beyond PAH

  4. 3. velj

    Gapping down: -1.8%, -1.6%, -1.2%, -1.2%, -0.7%, -0.6%, -0.6%, -0.5%

  5. 3. velj

    : a MoA that makes little sense frequently fails in cancer studies, especially when it’s a cocktail of nonsense. next.

  6. 3. velj
    Odgovor korisniku/ci
  7. 2. velj

    United Therapeutics Raised to “Hold” at BidaskClub

  8. 31. sij

    Baird downgrades Amgen on soft guidance in Friday pre market action ...

  9. 31. sij
  10. 30. sij

    United Therapeutics Earns “Buy” Rating from Wedbush

  11. 29. sij

    prevails against Sandoz in Remodulin litigation! Court just denied Sandoz's request for access to UTHR's Remodulin cartridges. The Remodulin franchise remains intact!

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.